On June 7, 2024, GSK plc announced the FDA's approval for its RSV vaccine, Arexvy, for adults aged 50-59 at increased risk, expanding its use from those aged 60 and older. The vaccine aims to protect over 13 million adults in this age group who have medical conditions that heighten their risk for severe RSV outcomes.